Innovaccer Inc. and St. Peter’s Health | June 01, 2022
Innovaccer Inc., the Health Cloud company, announced that St. Peter’s Health, a regional nonprofit healthcare system in Helena, Montana, is moving to the InnovaccerⓇ Health Cloud's Data Activation Platform to support its mission of providing exceptional and compassionate care that treats the whole person and improve the health, wellness, and quality of life for the communities it serves.
The health system, an integrated network with more than 100 providers, a 99-bed acute care hospital, physician and urgent care clinics, home health and hospice, ambulance services, cancer treatment services, and other ambulatory service lines, will be leveraging Innovaccer’s Best in KLAS Data Activation Platform to help providers collaborate across care sites by unifying the data from multiple EHRs to create a unified patient record that will support a new care management solution for optimized patient engagement.
“Transforming our legacy EHR data into unified patient records is an important step in enhancing access, patient engagement, and care management, as it builds on our strong foundation of patient-centered services. Our partnership with Innovaccer is a reflection of our ongoing commitment to provide the gold standard for exceptional care to our community.”
Ryan Winn, chief information officer, St. Peter’s Health
St. Peter’s Health will deploy several Innovaccer solutions to optimize the use of unified patient data. The health system will unify data from legacy EHRs to create an EHR-agnostic physician engagement solution that provides actionable clinical information at the point of care. In addition, St. Peter’s Health will use Innovaccer’s personalized care management solution to provide a wide range of workflows that assist care teams by simplifying tasks, bridging care and coding gaps, and supporting delivery of quality care outcomes. Lastly, Innovaccer’s AI-powered patient engagement solution will provide St. Peter’s Health with timely, clinically contextual patient insights that can enhance provider-patient collaboration.
“We’re thrilled that St. Peter’s Health is partnering with Innovaccer to accelerate their digital transformation,” said Abhinav Shashank, cofounder and CEO at Innovaccer. “We’re honored to be part of their journey and look forward to working closely with them to unlock the value of their patient data so they can advance their mission of delivering high-quality, low-cost, patient-centered care.”
About St. Peter’s Health
St. Peter’s Health is a nonprofit healthcare system located in Helena, Montana. Their services include but are not limited to a 99-bed acute care hospital, physician clinics, cancer treatment center, 24-bed behavioral health unit, urgent care clinics, home health and hospice care, dialysis center and ambulance services. They provide services to an estimated 97,000 residents from a five-county area. They are overseen by a volunteer board of directors that includes leaders and health experts who are committed to ensuring they provide exceptional healthcare to their community.
Innovaccer Inc., the Health Cloud company, is a leading San Francisco-based healthcare technology company committed to accelerating innovation in healthcare. The Innovaccer® Health Cloud unifies patient data across systems and settings, and empowers healthcare organizations to rapidly develop scalable, modern applications that improve clinical, operational, and financial outcomes. Innovaccer’s solutions have been deployed across more than 1,000 care settings in the U.S., enabling more than 37,000 providers to transform care delivery and work collaboratively with payers and life sciences companies. Innovaccer has helped organizations unify health records for more than 24 million people and generate more than $600 million in savings. Innovaccer is the #1 rated Data and Analytics Platform by KLAS, and the #1 rated population health technology platform by Black Book.
TapCloud | January 28, 2022
TapCloud, a technology leader in patient-directed care, will partner with Maxwell Healthcare Associates (MHA), a leading post-acute operational, financial, technological and regulatory consulting firm, to transform the post-acute industry with their innovative patient communication and artificial intelligence (AI) solution.
TapCloud's technology uses AI-driven tools to capture symptoms that automatically identify patients in need. The system supplies patients or their caregivers with words to indicate how they're feeling. The word cloud symptom tracker is unique to the patient, their-conditions, their medications and their history as it learns and evolves each time they use it.
MHA's reach and influence within the post-acute space is expansive, and their unique ability to connect industry partners with strategic solutions continues as they ally with TapCloud. They integrate result-orientated products and services to post-acute organizations that seek immediate answers for their problems. With MHA's organizational expertise and TapCloud's advanced solution, home health, palliative, and hospice providers will have the necessary tools to improve end-of-life care.
"We're very excited about 2022 and the opportunities that it will present us. TapCloud is an extraordinary organization that will enhance the care and communication with patients in the post-acute setting. Our goals at MHA are to equip our customers with tools that will not only enhance the care they provide but expose them to tools that have been vetted through our review process."
CEO of Maxwell Healthcare Associates,Jennifer Maxwell
President of TapCloud,Jolinda Lambert, shares in the enthusiasm and strongly believes the partnership will blossom into the new year. "Our product's ability to change how care is delivered is transformative. We can't wait to get started with MHA to help shape personalized care."
TapCloud is aChicago-based health-tech company founded in 2013. They produce an AI-driven application that provides better insights into a patient's symptoms and automatically identifies patients in need at the right time.
About Maxwell Healthcare Associates
Maxwell Healthcare Associates boasts an average of 20 years of experience in the post-acute space and has a pulse on what's relevant now in the industry. MHA can work with home health and hospice agencies to strategize, optimize and transform agencies across the nation.
FUTURE OF HEALTHCARE
NextGen Healthcare, Inc. | May 05, 2022
NextGen Healthcare, Inc. a leading provider of innovative, cloud-based healthcare technology solutions, announced a partnership with Circuit Clinical to bring clinical trial access to patients of Federally Qualified Health Centers through over 14,000 providers that utilize NextGen Healthcare solutions. Historically, these underserved communities have not had easy access to participate in transformative clinical research that can provide enhanced treatment options. Such research-as-care can also improve health outcomes and offers revenue generation for the clinics that participate. NextGen Healthcare’s innovative collaboration with Circuit Clinical, whose mission is to transform how patients find and choose clinical trials by bringing them to the doctors they know and trust, will improve the participation of diverse patients in clinical trials and provide greater health equity by facilitating access to the underserved.
“This partnership underscores NextGen Healthcare’s commitment to FQHCs and highlights our commitment to serving diverse patient populations. NextGen Healthcare’s technology is empowering providers to build healthier communities. Our work with Circuit Clinical is a milestone that provides real impact for our clients and their patients, and delivers on our pledge to facilitate better healthcare outcomes for all.”
Srinivas (Sri) Velamoor, chief growth and strategy officer at NextGen Healthcare
The collaboration contributes to the vision of the NextGen® Community Health Collaborative, a first-of-its-kind initiative announced late last year that offers data benchmarking, comparative analytics and reporting services, plus a forum for members to connect and share best practices to advance the mission of community health and health equity among underserved populations.
NextGen Healthcare-powered practices, in conjunction with Circuit Clinical, will now be able to offer clinical trial patient recruitment, referral and enrollment services, eliminating obstacles to such care. Furthermore, participation provides tangible benefits to participants, including extra care visits without co-pays, therapeutic improvement on a better regimen, and patient stipends.
“Our partnership with NextGen Healthcare will create a comprehensive solution for improving access to clinical trials for diverse communities across the country,” said Dr. Irfan Khan, founder and chief executive officer of Circuit Clinical. “Combining NextGen Healthcare’s comprehensive data insights and national reach with Circuit Clinical’s expert ecosystem offers pharmaceutical, biotech and vaccine companies a groundbreaking opportunity for accelerating therapeutic development and improving diversity in clinical trials.”
In April, the Food & Drug Administration (FDA) issued updated guidance to provide recommendations to those developing medical products on the approach for developing a Race and Ethnicity Diversity Plan to help enroll adequate numbers of participants in clinical trials from underrepresented racial and ethnic populations. Adequate representation in clinical trials helps ensure that the data generated reflects the racial and ethnic diversity of the intended use population and may potentially identify safety or efficacy outcomes, the FDA said.
About NextGen Healthcare, Inc.
NextGen Healthcare, Inc. is a leading provider of innovative healthcare technology solutions. We are reimagining ambulatory healthcare with award-winning solutions that enable high-performing practices to create healthier communities. We partner with medical, behavioral and dental providers in their journey toward whole-person health and value-based care. Our highly integrated, intelligent and interoperable solutions go beyond EHR and Practice Management to increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a quest to achieve better healthcare outcomes for all.
About Circuit Clinical
Circuit Clinical®, one of the largest integrated research organizations in the USA, is dedicated to empowering patients to choose clinical research as a care option. Circuit Clinical® is committed to transforming the way physicians and their patients find, choose, and participate in clinical research. The company delivers clinical research services and an award-winning patient engagement platform, trialjourney.com.
STENTiT | April 25, 2022
STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a regenerative stent (see video) for peripheral indications. The investment was made by Dutch investors NextGen Ventures, Brabant Development Agency and the Ten Cate Investment Company.
STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions by developing first-of-its-kind endovascular implants with regenerative capacity. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution.
As a first target indication, the company wants to improve the treatment of critical limb ischemia. This progressive form of peripheral artery disease affects almost 5 million people in the EU and the US in which the blood flow to the foot is severely being compromised. Unfortunately, current treatment options are ineffective, resulting in amputation within 6 months in 40% of these patients.
With the regenerative stent, blood flow to the foot will be maintained by securing vascular patency using temporary mechanical support and improving long-term efficacy by inducing vascular repair, thereby preventing thousands of amputations each year.
"We are excited to receive the support of these esteemed Dutch early-stage investors. This financing round validates our vision to bring a novel class of implants that can rebuild the affected blood vessels. We are looking forward taking the next steps getting our regenerative stents ready for clinical trials. With our first product, we aim to treat millions of patients suffering from peripheral artery diseases, and save their limbs from amputation."
Bart Sanders, CEO of STENTiT
STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out.
Since the establishment of the company, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-changing solution for millions of cardiovascular patients around the world.